Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : NACI advice to mix vaccines gets varied reaction from AstraZeneca double-dosers

06/18/2021 | 04:06am EDT

When Gwenny Farrell booked her second dose of the Oxford-AstraZeneca COVID-19 vaccine on the first day it became available, she said she believed she was doing the right thing.

The resident of White Rock, B.C., said she has tried to follow every health protocol and recommendation strictly, so her confidence has been shaken by a new recommendation from the National Advisory Committee on Immunization on mixing the vaccines.

On June 1, NACI had said AstraZeneca recipients "could" get Pfizer-BioNTech or Moderna for their second shot if they wanted, but on Thursday it went further to say an mRNA vaccine was the "preferred" choice.

"I'm frustrated because now, after being told for months that the best vaccine is the first one that's in your arm, I'm being told I may have made a mistake," Farrell, 55, said.

The new recommendation is drawing mixed reaction from those who've already received two jabs of AstraZeneca. Farrell is not alone in her disappointment, while others say they remain happy with their choice because they know it still means they are well protected against COVID-19.

The committee's guidance is based on the growing supply of mRNA vaccines, growing evidence that a second dose of an mRNA vaccine produces a stronger immune response, and because of the low but serious risk of vaccine-induced blood clots associated with AstraZeneca.

"People who received two doses of AstraZeneca/COVISHIELD vaccine can rest assured that the vaccine provides good protection against infection and very good protection against severe disease and hospitalization,'' NACI's advice says.

The committee also updated its previous recommendation that people at high risk of exposure to, or serious illness from, COVID-19, could opt to get AstraZeneca rather than waiting for Pfizer or Moderna. Now NACI says everyone should always get the mRNA vaccines first, unless they are allergic to them.

However, officials in Quebec and British Columbia didn't move to follow NACI's advice, instead saying residents can still make a personal choice for either a mixed schedule or two doses of AstraZeneca.

"The very real world evidence shows us we have good protection across the board with both vaccines in our community," B.C. provincial health officer Dr. Bonnie Henry said.

As of June 5, 2.1 million Canadians had received one dose of AstraZeneca, and 15,186 had received two doses.

There are no further shipments of AstraZeneca scheduled, but there are still about half a million doses of it in the provinces.

Toronto resident Sophie Nadeau said she remains grateful that she got her second AstraZeneca jab on Tuesday.

"I mean I'm fully vaccinated, that's amazing," she said.

Nadeau said she made the best decision she could with the information available at the time. As a single mother who hasn't been able to see her parents in a long time, it was important to get the first vaccine that was available.

As a public relations professional, Nadeau said she has a lot of empathy for those responsible for communicating what she understands to be naturally evolving recommendations as new evidence becomes available.

"There are no perfect choices when it comes to COVID-19," she said, adding the pandemic has made everyone develop risk assessment skills.

"I really do feel like for the last year and a half, every single thing has become an assessment of risk: from masks, to letting my kids out, to seeing my parents or choosing not to in this case. By this point, I've kind of become emotionally prepared for the story to change."

Mike Farnworth, British Columbia's minister of public safety, said he got his second AstraZeneca dose last week and would do the same if it was available this week.

He said his message to other British Columbians who have received two doses is the same: "Don't worry, you're fully vaccinated."

Others aren't so sure. Michael Slavitch, 54, made two separate appointments for his second dose because of mixed advice.

He now plans to cancel his AstraZeneca appointment Monday and keep his appointment for an mRNA shot.

Slavitch said he's particularly concerned about whether his AstraZeneca vaccine, or mixing and matching, will be accepted by other countries as international travel opens up.

"I'm confused about what to do," he said. "Our government is responsible for cleaning up this mess."

This report by The Canadian Press was first published June 18, 2021.

© 2021 The Canadian Press. All rights reserved., source Canadian Press DataFile

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.33% 8277 Delayed Quote.13.01%
MODERNA, INC. -1.05% 345.64 Delayed Quote.230.85%
All news about ASTRAZENECA PLC
07/29ASTRAZENECA : Emergent to resume J&J COVID-19 vaccine production at Baltimore pl..
07/29Exclusive - AstraZeneca exploring options for COVID-19 vaccine business - exe..
07/29AstraZeneca COVID-19 sales jump as drugmaker navigates vaccine challenges
07/29ASTRAZENECA : to seek US approval of COVID vaccine in 2nd half
07/29ASTRAZENECA : COVID-19 Jabs Supplied to Canada, Mexico From US Before Inspection..
07/29Exclusive-AstraZeneca COVID-19 vaccine shipped to Canada, Mexico before adequ..
07/29ASTRAZENECA : COVID-19 vaccine shipped to Canada, Mexico before adequate plant i..
07/29London Indexes Boosted by Positive Welcome to Most Earnings
07/29ASTRAZENECA : Oshikoto Youth Vaccine Hesitant
07/29ASTRAZENECA : H1 2021 results - AstraZeneca PLC
More news
Financials (USD)
Sales 2021 33 987 M - -
Net income 2021 5 413 M - -
Net Debt 2021 25 087 M - -
P/E ratio 2021 30,1x
Yield 2021 2,49%
Capitalization 179 B 179 B -
EV / Sales 2021 6,01x
EV / Sales 2022 4,70x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 115,58 $
Average target price 132,66 $
Spread / Average Target 14,8%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC13.01%179 111
JOHNSON & JOHNSON9.40%453 418
ROCHE HOLDING AG12.49%332 374
PFIZER, INC.16.25%243 220
NOVARTIS AG0.39%223 750